Zelira Therapeutics Limited (ASX:ZLD)

Australia flag Australia · Delayed Price · Currency is AUD
0.500
0.00 (0.00%)
Feb 27, 2026, 3:55 PM AEST
6.38%
Market Cap 5.95M
Revenue (ttm) 656.00
Net Income (ttm) -3.63M
Shares Out 11.90M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,140
Average Volume 10,153
Open 0.500
Previous Close 0.500
Day's Range 0.485 - 0.500
52-Week Range 0.310 - 1.150
Beta 0.63
RSI 39.87
Earnings Date Feb 19, 2026

About Zelira Therapeutics

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment product... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol ZLD
Full Company Profile

Financial Performance

In fiscal year 2025, Zelira Therapeutics's revenue was 656, a decrease of -99.31% compared to the previous year's 94,952. Losses were -3.63 million, -90.08% less than in 2024.

Financial Statements

News

There is no news available yet.